{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T23:19:50Z","timestamp":1795216790076,"version":"4.10.3"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Eltrombopag, a thrombopoietin receptor (TPO-R) agonist, is considered a second-line treatment for patients with refractory immune thrombocytopenia (ITP). Systemic lupus erythematosus (SLE) is frequently associated with ITP. In some cases, thrombocytopenia in SLE patients is attributed to concurrent antiphospholipid antibodies (APLA). Currently, data regarding treatment with TPO-R agonists for ITP in SLE or APLA patients are limited. The incidence of SLE flare or antiphospholipid syndrome while on TPO-R agonists has not been well-studied.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Cases:<\/jats:title>\n            <jats:p>We report 2 cases of female patients with SLE and concurrent triple positive APLA, without thrombotic events in their medical history, in our rheumatology clinic, who were treated for refractory ITP with eltrombopag. Both developed catastrophic antiphospholipid syndrome a few weeks after beginning treatment with eltrombopag. They were admitted to the intensive care unit and treated with solumedrol, plasmapheresis, anticoagulation and rituximab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>We describe a severe possible side-effect of eltrombopag as a trigger of catastrophic antiphospholipid syndrome, a rare initial manifestation of antiphospholipid syndrome, in SLE patients with APLA. We suggest that APLA should be tested before initiating eltrombopag in patients with SLE-associated ITP. The safety of this treatment should be considered in these cases.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032949","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T16:08:35Z","timestamp":1676045315000},"page":"e32949","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Catastrophic antiphospholipid syndrome in lupus-associated immune thrombocytopenia treated with eltrombopag A case series and literature review"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6363-5981","authenticated-orcid":false,"given":"Wakar","family":"Garra","sequence":"first","affiliation":[{"name":"Department of Internal Medicine E, Meir Medical Center, Kfar Saba, Israel"},{"name":"Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Or","family":"Carmi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine E, Meir Medical Center, Kfar Saba, Israel"},{"name":"Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel"},{"name":"Rheumatology Unit, Meir Medical Center, Kfar Saba, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaye","family":"Kivity","sequence":"additional","affiliation":[{"name":"Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel"},{"name":"Rheumatology Unit, Meir Medical Center, Kfar Saba, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Levy","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine E, Meir Medical Center, Kfar Saba, Israel"},{"name":"Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel"},{"name":"Rheumatology Unit, Meir Medical Center, Kfar Saba, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000511759","article-title":"Hematological manifestations among patients with rheumatic diseases.","volume":"144","author":"Klein","year":"2021","journal-title":"Acta Haematol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/1874312901307010087","article-title":"Hematological disorders in patients with systemic lupus erythematosus.","volume":"7","author":"Bashal","year":"2013","journal-title":"Open Rheumatol J"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1177\/0961203318770023","article-title":"Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series.","volume":"27","author":"Lusa","year":"2018","journal-title":"Lupus"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood.2021010968","article-title":"How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment.","volume":"137","author":"Ghanima","year":"2021","journal-title":"Blood"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/bjh.14788","article-title":"Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.","volume":"178","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Br J Haematol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/rheumatology\/key119","article-title":"Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists.","volume":"57","author":"Guitton","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1038\/s41598-021-84493-2","article-title":"Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease.","volume":"11","author":"Wang","year":"2021","journal-title":"Sci Rep"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.3899\/jrheum.140080","article-title":"Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.","volume":"41","author":"Magnano","year":"2014","journal-title":"J Rheumatol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/j.1538-7836.2010.03830.x","article-title":"Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP).","volume":"8","author":"Gernsheimer","year":"2010","journal-title":"J Thromb Haemost"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/RHU.0000000000001083","article-title":"Eltrombopag: efficacy and safety in steroid refractory lupus-associated immune thrombocytopenia.","volume":"26","author":"Shobha","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/ejh.13370","article-title":"Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia.","volume":"104","author":"Gonz\u00e1lez-L\u00f3pez","year":"2020","journal-title":"Eur J Haematol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1177\/0961203313477900","article-title":"Kidney-limited thrombotic microangiopathy in patients with SLE treated with romiplostim.","volume":"22","author":"Tomov","year":"2013","journal-title":"Lupus"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/j.semarthrit.2015.07.008","article-title":"Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist.","volume":"45","author":"LaMoreaux","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/0961203315608257","article-title":"Eltrombopag in systemic lupus erythematosus with antiphospholipid syndrome: thrombotic events.","volume":"25","author":"Boulon","year":"2016","journal-title":"Lupus"},{"key":"R15-20250504","first-page":"S0049","article-title":"Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostin, a thrombopoietin receptor agonist.","author":"LaMoreaux","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European league against rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus.","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/BOR.0000000000000595","article-title":"Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome.","volume":"31","author":"Vreede","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"R19-20250504","first-page":"9","article-title":"Thrombosis in patients with immune thrombocytopenia, review of literature.","volume":"136","author":"Maimoonah","year":"2020","journal-title":"Blood"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.scr.2012.05.001","article-title":"Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem\/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis.","volume":"9","author":"Sun","year":"2012","journal-title":"Stem Cell Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:01:10Z","timestamp":1746327670000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032949","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,10]]}}}